Nano Cap New Millennium Growth Fund L P Acquires Shares of 290,000 Personalis, Inc. $PSNL

Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 290,000 shares of the company’s stock, valued at approximately $2,308,000. Personalis comprises about 2.0% of Nano Cap New Millennium Growth Fund L P’s investment portfolio, making the stock its 8th largest position. Nano Cap New Millennium Growth Fund L P owned 0.33% of Personalis as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PSNL. Legal & General Group Plc bought a new position in shares of Personalis during the 2nd quarter valued at about $30,000. International Assets Investment Management LLC bought a new position in shares of Personalis during the 4th quarter valued at about $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the last quarter. Focus Partners Wealth bought a new position in shares of Personalis during the 1st quarter valued at about $47,000. Finally, FourThought Financial Partners LLC bought a new position in shares of Personalis during the 3rd quarter valued at about $86,000. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on PSNL. BTIG Research lowered their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Needham & Company LLC increased their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Guggenheim increased their price target on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Morgan Stanley lowered their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Performance

Personalis stock opened at $8.25 on Friday. The company has a 50 day moving average price of $6.55 and a 200-day moving average price of $8.03. Personalis, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $11.50. The company has a market capitalization of $863.94 million, a PE ratio of -8.09 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.